TerminatedNot Applicable

Post Marketing Trial for Evaluating the Effectiveness of ActiGraft in Treating Lower Extremity Hard To Heal Wounds

Stopped: low enrollment

Israel6 participantsStarted 2021-03-01

Plain-language summary

The study is a prospective, single arm, post- marketing study. The subjects enrolled to the study will receive weekly applications of ActiGraft until complete healing or until investigator's decision that patient can no longer benefit from the study treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subject is ≥18 years of age
✓. Patient with a chronic lower extremity ulcer (i.e DFU, VLU, …)
✓. Ulcer duration \>30 days.
✓. Ulcer size decreased in less than 30% in the 14 days prior to enrollment, while treated with standard of care (or advanced treatment)
✓. Subject must be willing to comply with the protocol including having blood drawn to create the ActiGraft
✓. Subject can read and understand the Informed Consent form

Exclusion criteria

✕. Presence of active underlying osteomyelitis.
✕. Known malignancy in the reference wound bed or margins of the wound
✕. Cannot withdraw blood in the required amount technically.
✕. Subject is receiving (i.e., within the past 30 days) systemic steroids (more than 10mg per day)
✕. Subject has been treated with wound dressings that include growth factors, engineered tissues or skin substitutes (within the past 30 days).
✕. Subject has been treated with hyperbaric oxygen, wound VAC or Ozone gas(O3) within the past 5 days or is scheduled to receive during the study

What they're measuring

Percent of Reduction in Wound Size Over 12 Weeks

Timeframe: 4, 8, and 12 weeks

Trial details

NCT IDNCT04745806

SponsorRedDress Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-01-01

View on ClinicalTrials.gov More Wounds trials